Q1 2025 Fulgent Genetics Inc Earnings Call Transcript
Key Points
- Fulgent Genetics Inc (FLGT) reported year-over-year growth in its Laboratory Services business, indicating strong momentum in 2025.
- The company's Therapeutic Development pipeline is progressing well, with FID-007 in Phase 2 trials and FID-022 set to begin Phase 1 trials soon.
- Precision Diagnostics saw a 17.8% year-over-year increase, driven by reproductive health services and Beacon Expanded Carrier Screening.
- The company has successfully onboarded new VA hospitals and is seeing significant usage, indicating potential upside from new initiatives.
- Fulgent Genetics Inc (FLGT) has a strong cash position with approximately $814.6 million in cash, cash equivalents, and marketable securities, supporting future growth and strategic initiatives.
- Revenue for the first quarter of 2025 was $73.5 million, a decrease from $76.2 million in the fourth quarter of 2024.
- Non-GAAP operating margins decreased approximately 5 percentage points sequentially to a minus 10%, primarily due to lower revenue and gross margins.
- The BioPharma Services business experienced a 33.7% sequential decline, reflecting the variability and timing of contracts in this segment.
- The company expects a non-GAAP loss of $0.65 per share for the full year 2025, indicating ongoing financial challenges.
- Despite strong performance in certain areas, the company did not raise its full-year guidance, suggesting caution regarding future uncertainties.
Greetings, and welcome to the Fulgent Genetics Q1 2025 conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to Melanie Solomon, Investor Relations. Please go ahead.
Thank you, Kevin. Good morning, and welcome to the Fulgent's first-quarter 2025 financial results conference call. On the call are Ming Hsieh, Chief Executive Officer; Paul Kim, Chief Financial Officer; and Brandon Perthuis, Chief Commercial Officer.
The company's press release discussing the financial results is available on the Investor Relations section of the company's website, ir.fulgentgenetics.com. A replay of this call will be available shortly after the call concludes on the Investor Relations section of the company's website.
Management's prepared remarks and answers to your questions on today's call will contain forward-looking statements. These forward-looking statements represent management estimates based on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
